NCT03206138View on ClinicalTrials.gov

Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

NAUnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Cervical Intraepithelial Neoplasia 3
Interventions
BIOLOGICAL

GX-188E, GX-I7

Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.

BIOLOGICAL

GX-188E, Imiquimod

1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.

Trial Locations (1)

06591

RECRUITING

Seoul St. Mary's hospital, Seoul

Sponsors

Collaborators (1)

Genexine, Inc.
All Listed Sponsors
collaborator

Genexine, Inc.

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER

NCT03206138 - Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod. | Biotech Hunter | Biotech Hunter